Literature DB >> 28429825

Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.

Seyed-Mohammad Fereshtehnejad1,2, Jacques Y Montplaisir3,4, Amelie Pelletier5, Jean-François Gagnon3,6, Daniela Berg7,8, Ronald B Postuma1,3.   

Abstract

BACKGROUND: Recently, the International Parkinson and Movement Disorder Society introduced the prodromal criteria for PD. Objectives Our study aimed to examine diagnostic accuracy of the criteria as well as the independence of prodromal markers to predict conversion to PD or dementia with Lewy bodies.
METHODS: This prospective cohort study was performed on 121 individuals with rapid eye movement sleep behavior disorder who were followed annually for 1 to 12 years. Using data from a comprehensive panel of prodromal markers, likelihood ratio and post-test probability of the criteria were calculated at baseline and during each follow-up visit.
RESULTS: Forty-eight (39.7%) individuals with rapid eye movement sleep behavior disorder converted to PD/dementia with Lewy bodies. The prodromal criteria had 81.3% sensitivity and 67.9% specificity for conversion to PD/dementia with Lewy bodies at 4-year follow-up. One year before conversion, sensitivity was 100%. The criteria predicted dementia with Lewy bodies with even higher accuracy than PD without dementia at onset. Those who met the threshold of prodromal criteria at baseline had significantly more rapid conversion into a neurodegenerative state (4.8 vs. 9.1 years; P < 0.001). Pair-wise combinations of different prodromal markers showed that markers were independent of one another.
CONCLUSION: The prodromal criteria are a promising tool for predicting incidence of PD/dementia with Lewy bodies and conversion time in a rapid eye movement sleep behavior disorder cohort, with high sensitivity and high specificity with long follow-up. Prodromal markers influence the overall likelihood ratio independently, allowing them to be reliably multiplied. Defining additional markers with high likelihood ratio, further studies with longitudinal assessment and testing thresholds in different target populations will improve the criteria.
© 2017 International Parkinson and Movement Disorder Society. © 2017 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; REM sleep behavior disorder (RBD); dementia with Lewy bodies (DLB); prodromal criteria

Mesh:

Year:  2017        PMID: 28429825     DOI: 10.1002/mds.26989

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  38 in total

1.  REM sleep muscle activity in idiopathic REM sleep behavior disorder predicts phenoconversion.

Authors:  Stuart J McCarter; David J Sandness; Allison R McCarter; John C Feemster; Luke N Teigen; Paul C Timm; Bradley F Boeve; Michael H Silber; Erik K St Louis
Journal:  Neurology       Date:  2019-08-16       Impact factor: 9.910

Review 2.  [Big data and artificial intelligence for diagnostic decision support in atypical dementia].

Authors:  K Egger; M Rijntjes
Journal:  Nervenarzt       Date:  2018-08       Impact factor: 1.214

Review 3.  Biomarkers of Parkinson's disease: 20 years later.

Authors:  Rezzak Yilmaz; Franziska Hopfner; Thilo van Eimeren; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2019-04-04       Impact factor: 3.575

Review 4.  Biomarkers for Parkinson's Disease: How Good Are They?

Authors:  Tianbai Li; Weidong Le
Journal:  Neurosci Bull       Date:  2019-10-23       Impact factor: 5.203

Review 5.  Sleep Disturbances in the Prodromal Stage of Parkinson Disease.

Authors:  Ahmed Al-Qassabi; Seyed-Mohammad Fereshtehnejad; Ronald B Postuma
Journal:  Curr Treat Options Neurol       Date:  2017-06       Impact factor: 3.598

Review 6.  Structural Imaging in Parkinson's Disease: New Developments.

Authors:  Stéphane Prange; Elise Metereau; Stéphane Thobois
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-18       Impact factor: 5.081

Review 7.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

Review 8.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

9.  Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.

Authors:  Anat Mirelman; Rachel Saunders-Pullman; Roy N Alcalay; Shiran Shustak; Avner Thaler; Tanya Gurevich; Deborah Raymond; Helen Mejia-Santana; Martha Orbe Reilly; Laurie Ozelius; Lorraine Clark; Mali Gana-Weisz; Anat Bar-Shira; Avi Orr-Utreger; Susan B Bressman; Karen Marder; Nir Giladi
Journal:  Mov Disord       Date:  2018-03-30       Impact factor: 10.338

Review 10.  New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Authors:  Lamya S Shihabuddin; Patrik Brundin; J Timothy Greenamyre; Diane Stephenson; S Pablo Sardi
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.